| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10745509 | Parkinsonism & Related Disorders | 2013 | 5 Pages |
Abstract
Histone deacetylation inhibition may represent a novel approach to reverse established LID in PD and improve quality of the anti-parkinsonian benefit provided by l-DOPA.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Tom H. Johnston, Philippe Huot, Sammie Damude, Susan H. Fox, Steven W. Jones, James R. Rusche, Jonathan M. Brotchie,